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OBJECTIVE — To evaluate the optimal interval for rechecking A1C levels below the diag-
nostic threshold of 6.5% for healthy adults.
RESEARCH DESIGN AND METHODS — This was a retrospective cohort study. Par-
ticipants were 16,313 apparently healthy Japanese adults not taking glucose-lowering medica-
tionsatbaseline.AnnualA1Cmeasuresfrom2005to2008attheCenterforPreventiveMedicine,
a community teaching hospital in Japan, estimated cumulative incidence of diabetes.
RESULTS — Mean age (SD) of participants was 49.7  12.3 years, and 53% were male.
Mean A1C at baseline was 5.4  0.5%. At 3 years, for those with A1C at baseline of 5.0%,
5.0–5.4%, 5.5–5.9%, and 6.0–6.4%, cumulative incidence (95% CI) was 0.05% (0.001–0.3),
0.05% (0.01–0.11), 1.2% (0.9–1.6), and 20% (18–23), respectively.
CONCLUSIONS — In those with an A1C 6.0%, rescreening at intervals shorter than 3
years identiﬁes few individuals (1%) with an A1C 6.5%.
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S
ince fasting and post-glucose chal-
lenge blood glucose levels were
found to predict the risk of diabetic
retinopathy, they have been the interna-
tionalstandardfordiagnosis(1).Recently,a
shift to A1C for diagnosis has been pro-
posed because A1C integrates longer-term
glucoselevelsandhasbetterpreanalyticsta-
bility (2). The proposed diagnostic thresh-
oldof6.5%wasbasedonretinopathyriskat
different levels of A1C (2). However, opti-
mal frequency for repeating A1C has not
been determined (3). We used a large, lon-
gitudinal dataset to explore the value of re-
peatingA1Catdifferentintervalstoidentify
subjects who might progress above the
threshold (6.5%).
RESEARCH DESIGN AND
METHODS— Between January and
December 2005, we consecutively en-
rolled all adults (aged 20 years) attend-
ing the Center for Preventive Medicine at
St. Luke’s International Hospital in To-
kyo, Japan, for the health check program.
The program promotes early detection of
chronic diseases and disease risk factors.
We excluded people who took glucose-
lowering medications at baseline.
Data collection
We extracted data from records of people
undergoing annual health checks from Jan-
uary2005toDecember2008.Weexcluded
thosewithouthealthchecksinyears1,2,or
3. St. Luke’s International Hospital Institu-
tional Review Board approved the study.
Measurements
The annual health check collected demo-
graphic information and medical history
with an initial evaluation (vital signs and
laboratory data). Laboratory data included
A1C,fastingplasmaglucose(FPG),andlip-
ids (total cholesterol, LDL cholesterol, and
HDLcholesterol).Venousbloodwasdrawn
after an overnight fast and analyzed at the
Central Laboratory at St. Luke’s Interna-
tionalHospital.A1Cassayswereperformed
byanautomatedglycohemoglobinanalyzer
(HLC-723G; Tosoh, Tokyo, Japan), with a
coefﬁcient of variation (CV) of 1.34%,
and certiﬁed by the National Glycohemo-
globin Standardization Program (4). We
classiﬁed subjects with either a single mea-
sured A1C 6.5% (5,6) or self-reported
commencement of glucose-lowering treat-
ment as diabetic. As a sensitivity analysis,
we used FPG 126 mg/dl as one of the
diagnostic criteria.
Statistical methods
For the analyses, we used SPSS software
15.0J (SPSS Japan, Tokyo, Japan), except
with 95% CIs, which were based on an
exactbinominal(7)usingStataversion10
(Stata, College Station, TX).
RESULTS— FromJanuary2005toJuly
2008, 16,313 people of the enrolled popu-
lation of 39,284 underwent annual checks.
Meanage(SD)ofparticipantswas49.7
12.3 years, and 53% were male. Mean BMI
was 22.5  3.2 kg/m
2; fasting plasma glu-
cose was 99.2  12.7 mg/dl; A1C at base-
line was 5.4 0.5%; total cholesterol, LDL
cholesterol, and HDL cholesterol levels at
baselinewere204.333.8mg/dl,117.6
29.7mg/dl,and62.415.8mg/dl,respec-
tively;andsystolicanddiastolicbloodpres-
sure was 119  18 mmHg and 73  11
mmHg, respectively. The trends of mean
A1C levels for the entire cohort from 2005
to 2008 slightly increased over 3 years
(0.05%peryear).Thedemographiccharac-
teristics of nonparticipants and participants
were similar.
At 3 years, the cumulative incidence
of diabetes was 3.2% (95% CI 3.0–3.4).
However,thisvariesgreatlybyinitiallevel
of A1C. At 3 years, for those with A1C of
5.0%, 5.0–5.4%, 5.5–5.9%, and 6.0–
6.4% at baseline, cumulative incidence
(95% CI) was 0.05% (0.001–0.3), 0.05%
(0.01–0.11), 1.2% (0.9–1.6), and 20%
(18–23), respectively, and adding FPG
126 mg/dl to the diagnostic criteria
showed similar results (Fig. 1). Logistic
regression suggested that only BMI (odds
ratio 1.14/kg/m
2) and FPG (1.06/mg/dl)
added to the baseline A1C; age, sex, sys-
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signiﬁcant. The average CV of A1C strat-
iﬁed by baseline A1C was 2.7% and did
not differ among these subgroups.
CONCLUSIONS — This study con-
ﬁrms that the rise in A1C in a nondiabetic
population is slow. Participants who are
well under the diagnostic threshold of
A1C 6.5% are unlikely to exceed this
within several years of follow-up.
Much of the increased detection of dia-
betes in those with a higher baseline A1C
was at 1 year and may be attributable to
measurement error and short-term varia-
tion in A1C. The CV (including within-
subject variation) varies between 2 and 5%
(8); a CV of 5% would mean that a 95%
measurementintervalofasingleA1Cinthis
rangewouldbe0.6%.Thisdegreeofvari-
ation would lead to some individuals hav-
ing sequential tests from just below to just
above 6.5%. Although the variation could
occur at all time points, this is much less
likely in the 5.0–5.9% range.
Our ﬁndings echo the slow rise of
A1Cfoundintrialswithdiabeticpatients.
For example, in the UK Prospective Dia-
betesStudy,thepatientsondietalonehad
a rise of 0.2% per year (9). Our nondi-
abetic cohort had an even lower average
change in A1C of 0.05% per year.
Thisstudyhasseverallimitations.First,
the follow-up is incomplete because not all
participants came back every year. This
could be addressed by other analysis, such
as a linear mixed model. However, any bias
would be likely to favor those developing
diabetes to reattend. Second, a few partici-
pants (1.1%) began taking glucose-
lowering drugs, but this is unlikely to make
alargedifferencetoourconclusions.Third,
our data are from one institution in Tokyo,
Japan, and might not generalize to other
populations. For example, adult mean BMI
levels of 22–23 kg/m
2 are found in Africa
and Asia, while levels of 25–27 kg/m
2 are
prevalent across North America and Eu-
rope,andthenBMIlevelcouldberelatedto
the cumulative incidence of diabetes. Fi-
nally, although the American Diabetes As-
sociation criteria recommend a repeat A1C
test to conﬁrm the diagnosis of type 2 dia-
betes (2), our study included only a single
measurement of A1C.
In conclusion, for the purpose of de-
tecting new cases of diabetes, in those
withaninitialA1C6.0%,rescreeningat
intervals shorter than 3 years identiﬁes
few individuals (1%) with an A1C
6.5%.AtA1C6%,rescreeningevenat
a 1-year interval would be reasonable
strategy to identify disease.
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Figure 1—Percent of patients at annual rechecks with A1C 6.5% or FPG 126 mg/dl (by baseline A1C).
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